What we're reading, September 1, 2016: new, stronger warnings on opioid labels; why competition hasn't curbed drug price hikes; and Zika funding bill likely won't pass the Senate.
The FDA will require strong warnings on opioids and certain anxiety medications. According to STAT, labels on these prescriptions will be required to alert doctors and patients about the risk of combining the two. Boxed warning labels on opioids and benzodiazepines will need to explain the danger of using the drugs with one another following a decade of increased prescribing of both classes of drugs and a rise in overdose deaths from using them together.
Why do drug prices continue to rise despite competition in the market? Since the United States allows drug manufacturers to set their own prices—unlike most other developed nations—prices for medicines continue to be higher than other countries in the world simply because companies can raise their prices, reported the Los Angeles Times. So even when 8 or more companies make the same decades-old drug, competition does little to keep the price down. One way to curb excessive price hikes is increased regulation, explained one expert.
The Zika fund may be close to running out, but there isn’t much hope that Congress will pass a bill requesting funding to fight the virus. The problem is that the Senate’s bill to provide $1.1 billion in Zika funding includes a rider that blocks funding for Planned Parenthood, according to CNN. Democrats have objected to the rider, which was one reason Congress left for summer recess without agreeing on legislation.
Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds
April 20th 2024The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More